Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

Literature DB >> 30633973

Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

Jiayi Pan¹, Livia P Mendes², Momei Yao¹, Nina Filipczak³, Sumanta Garai⁴, Ganesh A Thakur⁴, Can Sarisozen¹, Vladimir P Torchilin⁵.

Abstract

Multidrug resistance (MDR) significantly decreases the therapeutic efficiency of anti-cancer drugs. Its reversal could serve as a potential method to restore the chemotherapn>eutic efficiency. Downregulation of MDR-related proteins with a small interfering RNA (siRNA) is a promising way to reverse the MDR effect. Additionally, delivery of small molecule therapn>eutics simultaneously with siRNA can enhance the efficiency of chemotherapn>y by dual action in MDR cell lines. Here, we conjugated the dendrimer, generation 4 polyamidoamine (G4 PAMAM), with a polyethylene glycol (PEG)-phospholipid copolymer. The amphiphilic conjugates obtained spontaneously self-assembled into a micellar nano-preparation, which can be co-loaded with siRNA onto PAMAM moieties and sparingly water-soluble chemotherapeutics into the lipid hydrophobic core. This system was co-loaded with doxorubicin (DOX) and therapeutic siRNA (siMDR-1) and tested for cytotoxicity against MDR cancer cells: human ovarian carcinoma (A2780 ADR) and breast cancer (MCF7 ADR). The combination nanopreparation effectively downregulated P-gp in MDR cancer cells and reversed the resistance towards DOX.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: Chemotherapy; Combination delivery; Micelle; Mixed dendrimer micelles (MDM); Multidrug resistance; Polyamidoamine (PAMAM); siRNA delivery

Mesh：

Substances：

Year: 2019 PMID： 30633973 PMCID： PMC6377860 DOI： 10.1016/j.ejpb.2019.01.006

Source DB: PubMed Journal: Eur J Pharm Biopharm ISSN： 0939-6411 Impact factor: 5.571

55 in total

1. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.

Authors: M M Baekelandt; R Holm; J M Nesland; C G Tropé; G B Kristensen
Journal: Anticancer Res Date: 2000 Mar-Apr Impact factor: 2.480

2. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

Authors: M Maliepaard; M A van Gastelen; L A de Jong; D Pluim; R C van Waardenburg; M C Ruevekamp-Helmers; B G Floot; J H Schellens
Journal: Cancer Res Date: 1999-09-15 Impact factor: 12.701

3. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.

Authors: D Goren; A T Horowitz; D Tzemach; M Tarshish; S Zalipsky; A Gabizon
Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531

4. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups.

Authors: V P Torchilin; T S Levchenko; A N Lukyanov; B A Khaw; A L Klibanov; R Rammohan; G P Samokhin; K R Whiteman
Journal: Biochim Biophys Acta Date: 2001-04-02

5. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

Authors: Muthu Selvakumaran; Debra A Pisarcik; Rudi Bao; Anthony T Yeung; Thomas C Hamilton
Journal: Cancer Res Date: 2003-03-15 Impact factor: 12.701

6. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.

Authors: T Trippett; S Schlemmer; Y Elisseyeff; E Goker; M Wachter; P Steinherz; C Tan; E Berman; J E Wright; A Rosowsky
Journal: Blood Date: 1992-09-01 Impact factor: 22.113

Review 7. The role of glutathione-S-transferase in anti-cancer drug resistance.

Authors: Danyelle M Townsend; Kenneth D Tew
Journal: Oncogene Date: 2003-10-20 Impact factor: 9.867

Review 8. Survivin, versatile modulation of cell division and apoptosis in cancer.

Authors: Dario C Altieri
Journal: Oncogene Date: 2003-11-24 Impact factor: 9.867

9. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.

Authors: Henrik Gréen; Peter Söderkvist; Per Rosenberg; György Horvath; Curt Peterson
Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531

10. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.

Authors: Raquel T Lima; Luís M Martins; José E Guimarães; Clara Sambade; M Helena Vasconcelos
Journal: Cancer Gene Ther Date: 2004-05 Impact factor: 5.987

15 in total

Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

1. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.

2. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

3. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.

4. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups.

5. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

6. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.

Review 7. The role of glutathione-S-transferase in anti-cancer drug resistance.

Review 8. Survivin, versatile modulation of cell division and apoptosis in cancer.

9. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.

10. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.

1. Determination of Optimum Ratio of Cationic Polymers and Small Interfering RNA with Agarose Gel Retardation Assay.

Review 2. Craft of Co-encapsulation in Nanomedicine: A Struggle To Achieve Synergy through Reciprocity.

Review 3. Recent advances in anti-multidrug resistance for nano-drug delivery system.

Review 4. Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer.

Review 5. Evolution of drug-eluting biomedical implants for sustained drug delivery.

6. Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery.

7. Oleyl Conjugated Histidine-Arginine Cell-Penetrating Peptides as Promising Agents for siRNA Delivery.

8. Co-Delivery of Curcumin and Cisplatin to Enhance Cytotoxicity of Cisplatin Using Lipid-Chitosan Hybrid Nanoparticles.

Review 9. Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy.

Review 10. Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases.